Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gallbladder cancer
Results 1-25 of 36 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy in Treating Patients with Metastatic Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, NCT01174121
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SPI-1620-12-202, NCI-2013-01789, NCT01773785
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PrE0204, NCI-2014-02658, AX-CL-OTHER-PrECOG-004080, NCT02181634
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients with Advanced or Metastatic Biliary Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0524, NCI-2015-00578, NCT02392637
Dasatinib in Treating Patients with Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery and Has an IDH Mutation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00938, CA180-603, NCT02428855
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 470-12, NCI-2013-00406, NCT01825603
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC PHIXXXX, NCI-2014-02475, 9824, NCT02319018
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and over
Trial IDs: DEK-DKK1-P103, NCI-2015-00597, NCT02375880
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG881-C-002, NCI-2015-01150, NCT02481154
Start Over